Photo from wikipedia
Cytomegalovirus (CMV) is the most common opportunistic infection post‐transplant and is associated with significant morbidity and mortality. Currently, there are no FDA dosing recommendations for the use of valganciclovir for… Click to show full abstract
Cytomegalovirus (CMV) is the most common opportunistic infection post‐transplant and is associated with significant morbidity and mortality. Currently, there are no FDA dosing recommendations for the use of valganciclovir for the treatment of CMV infections in pediatric patients. This case series describes the use of valganciclovir for the treatment of CMV infections in nine pediatric intestinal transplant recipients (pITR).
Keywords:
infections pediatric;
case series;
transplant;
pediatric intestinal;
valganciclovir treatment
Journal Title: Pediatric Transplantation
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pediatric Transplantation
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!